Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine

Biological Psychiatry

Volumn 42, Issue 8, 1997, Pages 664-668

  Malhotra, Anil K ^a   Adler, Caleb M ^a   Kennison, Sasha D ^a   Elman, Igor ^a   Pickar, David ^a   Breier, Alan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Atypical antipsychotic; Clozapine; Ketamine; N methyl D aspartate; Psychosis; Schizophrenia

Indexed keywords

CLOZAPINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0030861444     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00546-X     Document Type: Article

References (26)

1. Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phenylcyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 271:1994;787-794.
2. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
3. Byrd LD, Standish LJ, Howell LL. Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol. 144:1987;331-341.
4. Cohen ML, Chan SL, Bhargava HN, Trevor AJ. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol. 23:1974;1647-1652.
5. Corbett R. Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol Biochem Behav. 51:1995;561-564.
6. Daly DA, Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett. 152:1993;61-64.
7. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
8. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
9. Kane J, Honigfeld G, Singer J, Meltzer H. Clozaril Collaborative Study Group, Clozapine for the treatment-resistant schizophrenic A double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-796.
10. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans Psychotomimetic, perceptual, cognitive, and neuroendocrine responses . Arch Gen Psychiatry. 51:1994;199-214.
11. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
12. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia An open-label trial . Biol Psychiatry. 39:1996;213-215.
13. Lidsky TI, Yablonsky-Alter E, Zuck L, Banerjee SP. Anti-glutamatergic effects of clozapine. Neurosci Lett. 63:1993;155-158.
14. Malhotra AK, Pickar D. Biologic predictors of clozapine response in schizophrenia. Psychiatr Ann. 26:1996;390-394.
15. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition The effects of ketamine in healthy volunteers . Neuropsychopharmacology. 14:1996;301-307.
16. Malhotra AK, Pinals DA, Adler Cm, Elman I, Clifton A, Pickar D, Breier A (1996b): Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology (In press).
17. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 55:(suppl 9B):1994;47-52.
18. Meltzer HY. Predictors of response to clozapine. Psychiatr Ann. 26:1996;385-389.
19. Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry. 55:(suppl 9B):1994;43-46.
20. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 10:1962;799-812.
21. Oye I, Hustveit O, Moberg ER, Pausen O, Skoglund LA. The chiral forms of ketamine as probes for NMDA receptor function in humans. Kameyama T, Nabeshima T, Domino EF. NMDA Receptor Related Agents Biochemistry, Pharmacology, and Behavior . 1991;381-389 NPP Books, Ann Arbor, MI.
22. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport HM. Clinical and biologic response to clozapine in patients with schizophrenia Crossover comparison with fluphenazine . Arch Gen Psychiatry. 49:1992;345-353.
23. Rothman S. Noncompetitive N-methyl-d-aspartate antagonists effect multiple ionic currents. J Pharmacol Exp Ther. 246:1988;137-142.
24. Smith DJ, Pekoe GM, Martin LL, Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci. 26:1980;789-795.
25. Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology. 20:1981;391-396.
26. Yamamoto BY, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci. 14:1994;4159-4166.